

Ref. No.: NLL/CS/2026- 697

July 23, 2026

To,

1. National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

Symbol: NECLIFE

2. BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001

Scrip Code: 532649

Sub.: Transfer of the Empty Hard Gelatin Capsule business ("Business") on a 'slump sale' basis

Ref.: Regulation 30 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations")

Dear Sir/ Madam,

This is in continuation of disclosures by Nectar Lifesciences Limited ("Company") regarding the transfer of Business on a 'slump sale' basis vide letter no. NLL/CS/2025- WFH dated December 20, 2025, along with Annexure 1 thereto and letter no. NLL/CS/2026- 675 dated April 28, 2026.

In this regard, please be informed that the Company and Capnest Health Care Private Limited ("Purchaser") have mutually agreed to extend the expected completion date of such slump sale to, on or before December 31, 2026.

The other relevant disclosures pertaining to slump sale as required under LODR Regulations, have already been provided as per Annexure no. 1 to aforesaid letter no. NLL/CS/2025- WFH dated December 20, 2025, shall remain the same.

This is for your information and record please.

Thanking you,

Yours faithfully,

For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)

Company Secretary & Compliance Officer